Pipeline

Internal Programs Early Research Pre-Clinical Phase 1 Phase 2 Phase 3
Etrasimod
GI
ELEVATE UC 52

95%

ELEVATE UC 12

95%

GLADIATOR UC

73%

CULTIVATE (CD)

95%

VOYAGE (EoE)

73%

Derm
ADVISE – Atopic Dermatitis (AD)

95%

Alopecia Areata (AA)

73%

CR
Controlled Release

58%

Olorinab
GI
CAPTIVATE IBS-C/D

73%

APD418
CV
Acute HF (AHF)

73%

Research Partnership Early Research Pre-Clinical Phase 1 Phase 2 Phase 3
Project Cabrillo
Early Stage Immune & Inflammatory Platform w/ Beacon
Target 1

20%

Target 2

15%

Additional Targets

15%

Partnered / Licensed Programs Early Research Pre-Clinical Phase 1 Phase 2 Phase 3
Ralinepag
UTHR
PAH

95%

Multiple Assets
Longboard
LP352

50%

LP143

25%

LP659

20%

Additional Targets

15%

Undisclosed Orphan GPCR
BI
CNS

30%

Program Indication Phase
Internal Programs
Etrasimod
ELEVATE UC 52 Ph3
ELEVATE UC 12 Ph3
GLADIATOR UC Ph2b Planning
CULTIAVTE (CD) Ph2/3
VOYAGE (EoE) Ph2b Planning
ADVISE – Atopic Dermatitis (AD) Ph3 Planning
Alopecia Areata (AA) Ph2 Planning
Controlled Release (CR) Ph1
Olorinab
CAPTIVATE (IBS-C/D)) Ph2b
APD418
Decompensated HF (DHF) Ph2
Research Partnerhip
Project Cabrillo
Target 1 Early Research
Target 2 Early Research
Additional Targets Early Research
Partnered / Licensed Programs
Ralinepag
PAH Ph3
Longboard
LP352 Ph1
LP143 Early Research
LP659 Early Research
Additional Targets Early Research
Undisclosed Orphan GPCR
CNS PC

Last updated as of 10/24/2020